Company profile for Veloxis Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed ENVARSUS XR (tacrolimus extended-release tablets...
Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed ENVARSUS XR (tacrolimus extended-release tablets) based upon the company’s unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1001 Winstead Drive, Cary, NC 27513
Telephone
Telephone
1 919 591 3090
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-to-present-at-2025-world-transplant-congress-302516650.html

PR NEWSWIRE
30 Jul 2025

https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-receives-approval-from-usan-for-pegrizeprument-as-nonproprietary-name-for-vel-101-302384616.html

PR NEWSWIRE
25 Feb 2025

https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-selected-to-present-at-the-2024-american-transplant-congress-in-philadelphia-302158666.html

PR NEWSWIRE
30 May 2024

https://www.prnewswire.com/news-releases/lyfebulb-and-veloxis-pharmaceuticals-announce-finalists-for-2022-innovation-challenge-in-organ-transplantation-301627424.html

PRNEWSWIRE
19 Sep 2022

https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-announces-dosing-of-the-first-patient-by-partner-xenikos-in-the-global-phase-3-study-evaluating-t-guard-in-patients-with-steroid-refractory-acute-graft-versus-host-disease-sr-agvhd-301576083.html

PRNEWSWIRE
28 Jun 2022

https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-announces-dosing-of-the-first-participant-in-a-phase-i-study-of-vel-101-a-novel-investigational-drug-for-kidney-transplant-immunosuppression-301549664.html

PRNEWSWIRE
18 May 2022

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty